A drug that clears ‘zombie cells’ has been tested in humans for the first time
Ageing cells that refuse to die accumulate in our bodies and cause widespread damage. A new drug can now selectively eliminate them in humans — the first data are in.
Rubedo Life Sciences has published results from a phase 1 trial of RLS-1496, a new type of senolytic — a compound designed to selectively kill so-called senescent cells, sometimes called ‘zombie cells’. Senescent cells are those that have stopped dividing but refuse to die. They accumulate as we age and secrete substances that damage surrounding healthy tissue, drive chronic inflammation, and impair the body’s ability to repair itself. They have been linked to dozens of age-related conditions, from joint degeneration to pulmonary fibrosis.
RLS-1496 targets a protein called GPX4, which helps senescent cells survive. By blocking it, the cell loses its survival mechanism and dies. The phase 1 trial deliberately took a cautious route: rather than administering the drug systemically through the bloodstream, it was applied topically to the skin in patients with a skin condition where senescent cells are known to play a significant role. This limits the risk of side effects elsewhere in the body.
Why early data still matter
Phase 1 trials are primarily about safety, not efficacy. Even so, the first human data carry real significance. Until now, most evidence for senolytics came from animal models — primarily mice. The question has always been whether the mechanisms translate to humans as expected. The fact that RLS-1496 has completed a phase 1 study without serious adverse events is already informative. GPX4 is also a different target from first-generation senolytics like dasatinib and quercetin, which have been studied for longer. A new mechanism of action that appears safe in early testing potentially expands the therapeutic toolkit.
The senolytic biotech sector has faced a difficult investment climate for the past three years. Multiple companies have slowed or shelved their programmes. Rubedo’s topical delivery strategy follows a logic similar to Life Biosciences’ eye trial: it is considerably easier to gain regulatory approval for a specific skin condition than for ‘ageing in general’. Whether that approach scales to the broader applications the company ultimately has in mind remains to be seen.
The bigger picture: a field still waiting for its first clear win
Senolytics are one of the best-supported approaches in longevity medicine. The theory is solid, the animal data are compelling, and dozens of clinical studies are now underway worldwide. But translating mouse results into human medicine is notoriously difficult, and senolytics are no exception. Earlier clinical results — in pulmonary fibrosis and knee osteoarthritis, among others — have been promising but not definitive. RLS-1496 is the latest candidate in a field still waiting for its first unambiguous clinical breakthrough.